(2021). Palbociclib Plus Fulvestrant Maintains Long‐Term Overall Survival Benefit in HR+/HER2– Advanced Breast Cancer. Oncologist.
Παραπομπή Chicago Style"Palbociclib Plus Fulvestrant Maintains Long‐Term Overall Survival Benefit in HR+/HER2– Advanced Breast Cancer." Oncologist 2021.
Παραπομπή MLA"Palbociclib Plus Fulvestrant Maintains Long‐Term Overall Survival Benefit in HR+/HER2– Advanced Breast Cancer." Oncologist 2021.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.